Skip to main content
OpenTrials
Recruiting

NCT Number: NCT04192253

Treatment of Locally Advanced VULvar CArcinoma in a Neoadjuvant Setting With Carboplatin and Paclitaxel Chemotherapy (VULCANize)

Vulvar cancer is a rare malignancy. Surgery is the treatment of choice, but frequently causes invalidating and chronic postoperative morbidity, especially in patients with high stage disease. Theoretically, downstaging with neoadjuvant chemotherapy could shrink the tumour, making surgical treatment less extensive thereby diminishing the chance for morbidity.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

Female

Study type

Interventional

Phase

Phase 2

Primary location

NKI-AVL

Amsterdam, 1066CX, Netherlands

Location status: Recruiting

Location contact

Henry Zijlmans, MD, PhD

PRINCIPAL_INVESTIGATOR

NKI-AVL Zijlmans, MD, PhD

CONTACT

[email protected]

0031205129111

About this study

Vulvar cancer is a rare malignancy. Surgery is the treatment of choice, but frequently causes invalidating and chronic postoperative morbidity, especially in patients with high stage disease. Theoretically, downstaging with neoadjuvant chemotherapy could shrink the tumour, making surgical treatment less extensive, thereby diminishing the chance for morbidity.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Woman k 18 years
  • Signed and written informed consent.
  • Histologically confirmed squamous cell vulvar carcinoma
  • World Health Organization performance status of 0-2
  • Adequate hematological function
  • Adequate hepatic function
  • Adequate renal function
  • Negative pregnancy test for woman of childbearing potential
  • measurable disease by physical examination
  • TNM stage T2, any N, MO

Exclusion criteria

  • Vulvar cancer other than squamous cell carcinoma at biopsy
  • Previous radiotherapy of the vulva, groins or pelvis
  • Patients with metastasis limited to the pelvic lymph nodes, who can be primarily operated with curative intent
  • Other diagnosis of malignancy or evidence of other malignancy for 5 years before screening for this study

Treatment and study plan

Paclitaxel and Carboplatin

Drug

Paclitaxel 175 mg/m2 and Carboplatin AUC 5 in a 3 weekly schedule

Primary outcomes

  1. tumour size change by neoadjuvant chemotherapy

    Time frame: 18 weeks

    tumour size change by neoadjuvant chemotherapy measured by RECIST 1.1

Secondary outcomes

  1. avoidance of exenterative or invalidating surgery

    Time frame: 21 weeks

    number of patients were surgery can be reduced after the neo-adjuvant chemotherapy

  2. Chemotherapy related morbidity

    Time frame: 21 weeks

    Chemotherapy related morbidity measured by reported adverse events

  3. overall survival

    Time frame: 5 years after treatment

    overall survival

Study contacts

Contact information is provided by the study sponsor or research team.

Frederic Amant, MD, PhD

CONTACT

[email protected]

0031205129111

Sponsors and collaborators

Lead sponsor

The Netherlands Cancer Institute

Other

Registry information

Acronym: VULCANize

Important dates

Study start
2020
Primary completion
2024
Study completion
2029
First posted
Dec 10, 2019
Registry last updated
Oct 19, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.